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Dementia is a complex clinical condition characterized by several cognitive impairments that interfere with patient independence
in executing everyday tasks. Various neurodegenerative disorders have dementia in common among their clinical manifestations. In
addition, these diseases, such as Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies and frontotemporal
dementia, share molecular alterations at the neuropathological level. In recent years, the ﬁeld of neuroepigenetics has expanded
massively and it is now clear that epigenetic processes, such as DNA methylation, are mechanisms involved in both normal and
pathological brain function. Despite the persistent methodological and conceptual caveats, it has been reported that several genes
fundamental to the development of neurodegenerative disorders are deregulated by aberrant methylation patterns of their
promoters, and even common epigenetic signatures for some dementia-associated pathologies have been identiﬁed. Therefore,
understanding the epigenetic mechanisms that are altered in dementia, especially those associated with the initial phases, will
allow us not only to understand the etiopathology of dementia and its progression but also to design effective therapies to reduce
this global public health problem. This review provides an in-depth summary of our current knowledge about DNA methylation in
dementia, focusing exclusively on the analyses performed in human brain.
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INTRODUCTION
Current demographic trends are leading to a world population
comprising a higher proportion of older people. By 2050, for the
ﬁrst time in history, there will be fewer young people than older
people.1 This not only poses a major environmental problem2 but
will also give rise to an incalculable worldwide socioeconomic
burden because of age-related disorders. At present, more than 48
million people worldwide live with dementia and it is estimated
that, owing to the lack of preventative therapeutics, there will be
more than 130 million patients by 2050.3 The estimated global
cost of dementia is US$818 billion for 2016,4 although this ﬁgure
does not take into account the incalculable social and health costs
to relatives and other caregivers.
Dementia is not deﬁned as a speciﬁc disease but rather as a
collection of cognitive impairments caused by a plethora of
disorders. Typically, dementia symptoms include impaired cogni-
tive functions such as loss of memory, language and construc-
tional skills, which are often accompanied by behavioral
alterations such as delusions or agitation. Clinical diagnosis of
dementia requires the manifestation of two core features
characterized by a loss of intellectual ability of sufﬁcient severity
to interfere with the patient’s independence.5 Some of the
diseases that feature dementia are Alzheimer’s disease (AD),
Parkinson’s disease (PD), dementia with Lewy bodies (DLB) and
frontotemporal dementia (FTD; Pick’s disease).6
Recent investigations have indicated that neuroepigenetic
mechanisms are key players in dementia-associated disorders,
supporting the hypothesis that the accumulation of epigenetic
alterations over the lifespan could be a mechanism underlying
these disorders (the ‘Latent Early-life Associated Regulation’
(LEARn) model).7,8 Neuroepigenetic processes are complex
mechanisms that regulate the transcriptome of brain cells in
serving several functions, such as learning and memory,9 and in
the aging process10–12 and pathological states.13 Epigenetic
mechanisms are characterized by their ability to alter transcription,
by changing the chromatin structure without modifying the DNA
sequence.14 The best understood type of epigenetic modiﬁcation
is DNA methylation,15 which occurs by covalently adding a methyl
group from S-adenosyl methionine to the 5′ position of cytosines
(5 mC) linked by a phosphodiesterase bond to guanines (CpG
dinucleotides). Promoter regions of coding genes (~70% of human
genome promoters) are frequently highly enriched in CpGs,
forming the CpG islands.16 DNA methylation is generally
considered to be a repressive mark17,18 that principally attracts
other proteins associated with gene silencing.19 The addition of
methyl groups to the DNA is catalyzed by a set of enzymes called
DNA methyltransferases (DNMTs), a group formed by DNMT1,
DNMT2 and DNMT3 proteins.20 All of these proteins are strongly
expressed in neurons,21 although their function is quite different.
While DNMT1 is responsible for maintaining the methylation
pattern after cell division,22 DNMT3a and DNMT3b are responsible
for the de novo methylation.23,24 DNA methylation is a reversible
process owing to the function of the TET proteins that, through
the oxidation of the methyl group, lead the conversion of 5 mC in
5-hydroxymethylcytosines (5 hmC),25 which after successive con-
versions to 5-formylcytosine and 5-carboxycytosine deﬁnitively
erase the epigenetic mark. Brain cells are particularly highly
enriched in 5 hmC,26 and it has been postulated that it is not
merely an intermediate state in the demethylation process but, in
fact, a key epigenetic mark in neurological disorders.27,28
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Alterations in the DNA methylation pattern have been seen in
other cellular genomes, such as that of the mitochondria. The
mitochondrial genome (mtDNA) is small (16.6 kb) and comprises
37 genes. Although it does not contain CpG islands it is highly
regulated by DNA methylation processes.29,30 The existence of
both 5 mC and 5 hmC in the mtDNA30 and the presence of
mitochondrial DNMT and TET proteins have been conﬁrmed.30,31
Several laboratories have recently turned their attention to the
role of the (hydroxy)methylome of mtDNA and its function
regulating gene expression.32 Little is known about brain mtDNA
methylation but we do know that increased 5 hmC levels are
associated with aging in mice.33
Several disorders with an apparently diverse spectrum of
symptoms feature dementia. Surprisingly, those brain alterations
exhibit similar molecular alterations, in spite of the observed
neuroanatomical differences in the affected areas among these
disorders. For example, amyloid plaques, a hallmark of AD, are also
formed in DLB, and Tau alterations are common in AD, PD, DLB
and FTD.34–39 These disorders even have similarities at the genetic
level, where it has been shown that DLB is equally correlated with
AD and PD,40 implying that similar mechanisms are involved
(Figure 1). However, it is also possible that different set of
alterations or perturbation in brain cells lead to similar response at
the genetic level. Our laboratory has recently demonstrated that
several dementia-related neurodegenerative disorders (AD, PD,
DLB and Down syndrome) share a common set of genes
undergoing aberrant DNA methylation shifts.41 These genes,
which are involved in functions such as cortex development and
general gene regulation, highlight the importance of epigenetic
alterations in disorders associated with dementia, despite the
limiting number of articles performing cross-disorder proﬁles. In
this review, we will focus on the role of DNA (hydroxy)methylation
in dementia-related disorders by summarizing the current knowl-
edge of the role of this particular epigenetic modiﬁcation in
human neurodegeneration. Overall, relevant gene targets for
altered DNA methylation in dementia are illustrated in Figure 2,
whereas Figure 3 shows the intracellular location of the encoded
proteins. The next sections will analyze in detail these epigenetic
changes across the broad spectrum of clinical entities associated
with dementia.
ALZHEIMER’S DISEASE
AD is the leading form of dementia worldwide. It is an age-related
neurodegenerative disorder that severely impairs memory and
other cognitive functions. Although clinical manifestations typi-
cally occur in patients over 65 years of age, AD develops over
decades, and it is believed that the ﬁrst pathogenic processes start
several decades before typical symptoms manifest
themselves.42,43 At the molecular level, AD is characterized by
the appearance of two neuropathological hallmarks: senile
plaques, comprising insoluble aggregates of amyloid β, and
neuroﬁbrillary tangles, which are comprised of abnormally
hyperphosphorylated Tau.44,45 Although the scientiﬁc community
has amassed considerable knowledge of the molecular alterations
and temporal progression of the disease, the events driving the
origin of the disorder are unknown. Genetic and non-genetic
factors contribute to the etiopathology of AD. To date, almost 300
mutations have been associated with familiar AD, especially those
in the APP, PSEN1 and PSEN2 genes.46 However, only ~ 5% of all AD
cases are mainly caused by genetic factors, which draws attention
to the need to decipher the non-genetic causative factors of late-
onset AD, which is most likely triggered by environmental stimuli
that participate in the appearance of AD.
In the past few years, researchers have begun to realize that
epigenetic mechanisms are key players in the development/
course of AD. Age-associated alterations at the levels of 5 mC and
5 hmC and other epigenetic marks47,48 have been associated with
the progression of AD.49,50 Several AD-associated genes have
been analyzed at the epigenetic level. The APP gene has been
described, by using targeted approaches, as hypomethylated in
multiple CpG sites on its promoter,51–53 a concomitant ﬁnding
with the upregulated levels of APP found in AD brains. These
studies used a small cohort, and the ﬁndings could not be
conﬁrmed in a larger cohort.54 These conﬂicting results highlight
the necessity of performing better and more in-depth studies on
the regulation of the APP gene by epigenetic mechanisms. Other
APP-related genes, such as APOE, Nicastrin and BACE1 (which is
hypomethylated in peripheral blood mononuclear cells of AD
patients55), were found to be unaltered in AD brain samples,
whereas PSEN1 was hypomethylated and other genes, such
MTHFR and DNMT1, were hypermethylated.56 Analyses involving
matrix-assisted laser desorption ionization-time of ﬂight mass
spectrometry are difﬁcult to interpret, especially because of the
small sample sizes used and the high interindividual variance
observed, particularly in the PSEN1 and APOE genes. Interestingly,
SORL1 and ABCA7, which are genes related to Aβ production, were
found to be hypermethylated in AD brains.57 Methylation levels of
other genes associated with the amyloid machinery, such as
DIP2A, SERPINF1, SERPINF249 and TMEM59,58 are also altered,
although the speciﬁc meaning of such ﬁndings needs to be
rigorously addressed. Importantly, the DNA methylation altera-
tions found in De Jager et al.49 correlated with the burden of
amyloid plaques identify on the brain tissue, thus associating their
ﬁnding to the neuropathological state of the subjects.
Other targeted analyses of key molecular players of AD have
shown epigenetic alterations in the Tau cascade. Our team
demonstrated that DUSP22, a phosphatase-targeting abnormal
Tau, presents a hypermethylated promoter in AD that is associated
with the lower levels of the protein described in the pathology.59
The levels of methylation of DUSP22 correlated positively with
Braak stage of the AD patient. Accordingly, the promoter of the
DUSP6 gene, another phosphatase that regulates Tau, was found
Figure 1. Schematic representation of the known connections
between Alzheimer’s disease, Parkinson’s disease, dementia with
Lewy bodies and frontotemporal dementia. These disorders not
only feature dementia as one of their core clinical manifestations
but also share neuropathological alterations such as amyloid-β
accumulation, Tau alterations (hyperphosphorylation or loss of
function) and α-synuclein aggregation (Lewy bodies).
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to be hypermethylated in AD brain60 using a genome-wide
approach. Although TAU promoter is not regulated via DNA
methylation,54 the data obtained indicate that the molecular
cascade associated with Tau hyperphosphorylation or depho-
sphorylation may be deregulated epigenetically in AD. In another
genome-wide study, other molecules associated with Tau altera-
tions, such as BIN1,61 were found to be aberrantly hypermethy-
lated in AD,49,57 a change correlated with the amyloid plaques
burden. Other molecules associated with neuronal function and
ﬁring potentials, such as SPTBN4 (spectrin beta 4), are down-
regulated in human AD brains, a ﬁnding that correlates with the
hypermethylation status of its promoter.62 SPTBN4 not only
participates in the formation of the axon initial segment but also
anchors CaMKII to it. CaMKII mislocalization, due to a loss of
SPTBN4, is a plausible mechanism for Tau hyperphosphorylation.63
Overall, those sets of data indicate that the two major molecular
hallmarks in AD could be regulated via DNA methylation in the
early and late phases of the disorder.
Several studies have highlighted the importance of epigenetic
processes in the gene expression deregulation occurring in AD, in
addition to identifying the AD hallmarks. By analyzing the frontal
cortex of human post-mortem samples of AD patients, two
independent groups found AD-associated hypermethylation of
the promoter of SORBS3, a protein involved in synaptic
function.62,64 Although this effect has been associated with
normal aging, this hypermethylation seems to occur faster in
AD. Recently, epigenome-wide association studies have identiﬁed
ANK1 (ankyrin1) as a potential biomarker of AD, as its methylation
level is strongly correlated with early stages of the disease and
strongly associated with Braak score of the patient. In AD, it is
downregulated via hypermethylation of its promoter.41,49,65 Little
is known about ANK1 function, but it seems to be related to
microglia activation and cell motility. Other molecules associated
with the immune response show aberrant methylation states. For
example, RHBDF2 (related to TNFα function) and HLA-DRB5 are
hypermethylated, and nuclear factor-κB (NF-κB) and COX2
(cyclooxygenase-2), which are proinﬂammatory and associated
with inﬂammatory events in AD, are hypomethylated.41,49,57,66,67
Mutations of the gene coding for TREM2 (triggering receptor
expressed in myeloid cells 2) have been associated with an
increased risk of suffering AD.68,69 TREM2 is expressed in microglia
and is associated with microglia activation, phagocytosis and the
immune response.70 TREM2 mRNA levels are upregulated in AD
hippocampus, its mRNA levels being positively correlated with the
AD Braak stages. Interestingly, the increase in mRNA levels are
accompanied by a Braak-associated hypermethylation of the
TREM2 promoter.71 These results are not those expected from the
methylation of promoters, which are normally associated with
gene repression, and further research is needed to understand
these effects. Overall, synaptic degeneration and immune changes
are some of the best known alterations in the pathophysiology of
AD,72,73 and there are evidences that suggests that those are
inﬂuenced by epigenomic modiﬁcations.74
Other molecules have been identiﬁed as being epigenetically
deregulated in AD. Demyelination processes have been associated
with aging but are accelerated in AD, and a recent study has
shown that transcriptional alterations in myelination-associated
proteins, such as WIF1 and RARRES3, may be mediated via DNA
methylation changes.75 SLC2A4, which is thought to be involved in
neural development, is also hypermethylated in AD brains.57
Glucose metabolism in brain is altered in this pathological state76
via deregulation of the brain insulin signaling cascade.77,78
Regarding this pathway, IGFBP7 (insulin-like growth factor binding
protein 7) is upregulated in the brains of AD patients probably
because of the hypomethylated state of its promoter.79 This
protein binds to insulin growth factors and attenuates its
protective effects.80 Rao et al.66 demonstrated that the reduction
in brain-derived neurotrophic factor previously observed in AD81
was probably due to hypermethylation of its promoter. This










































































Figure 2. Illustration to summarize the major DNA (hydroxy)methylation changes described to date in Alzheimer’s disease (AD), Parkinson’s
disease (PD), dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD) among different brain regions. Red, hypermethylated
genes in the disorder; green, hypomethylated genes in the disorder.
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was accompanied by a similar one at the promoter of the cAMP
response element-binding protein (CREB).66 Both brain-derived
neurotrophic factor and CREB are critical proteins for neuronal
survival.82,83 Other authors have also described alterations in
genes related to CREB signaling, such as hypermethylation of
TBXA2R (thromboxane A2 receptor) gene promoter,62 a G-protein
receptor regulating CREB, thereby highlighting the importance of
CREB signaling in AD.84
Besides studying the 5 mC levels in AD, researchers have begun
to analyze the role of 5 hmC in health and disease. The central
nervous system is especially enriched in 5 hmC relative to other
body tissues,26 and exhibits a speciﬁc pattern across the different
brain areas.85 5 hmC is considered to be a key epigenetic mark in
brain development and neurological disorders,27,28 leading
reearchers to postulate that age-associated neuronal 5 mC/5mhC
changes may be involved in the early and late phases of AD. There
are lower 5 hmC levels in several brain regions of late stages of AD
patients, such as the neocortex,86 hippocampus,87 entorhinal
cortex and cerebellum.88 A genome-wide study has recently found
several genes to be associated with neuronal morphology and
synaptic function with aberrant 5 hmC levels in the prefrontal
cortex of AD patients. Bernstein et al.89 found differential 5 hmC
levels of ANK1, DIP2A, BIN1 and DUSP22 genes among those genes
described as being epigenetically altered in AD.41,49,59,65 TREM269
also presents alterations in 5 hmC levels in AD brains, insofar as
there is a correlated increase in 5 hmC levels in exon 2 and TREM2
mRNA levels.71 However, there are several controversies regarding
this epigenetic mark, reﬂecting the need for further studies to
determine the exact role of 5hmC in AD. For example, there are
raised levels of 5 hmC in the hippocampus90 and temporal gyrus50
of AD patients. These discrepancies could have arisen as a result of
studying different brain populations (i.e. entorhinal cortex vs
hippocampus vs temporal gyrus) but also for technical reasons (i.e.
immunohistochemistry vs western blotting or dot blot).
Owing to the fact that mitochondrial alterations have been
found in AD,91–93 scientiﬁc community have started to analyze the
role of the (hydroxy)methylome of mtDNA in brain (mal)
function.32 In the context of AD, Blanch et al.94 found a global
reduction of 5 mC in mtDNA in mid–late stages of AD (Braak III/IV).
Analysis of speciﬁc loci showed that the levels of 5 mC in MT-ND1,
a protein of the complex I of the respiratory chain, were lower in
the entorhinal cortex of AD patients compared with that in age-
matched controls. However, no changes were noted in 5 hmC of
the mtDNA of AD samples despite that it was described previously
as a reduction in 5 hmC levels in aging-associated mtDNA.33 The
discrepancy between the Blanch and Dzitoyeva studies could be
due to differences between species (humans vs mice, respectively)
and the methods used (hydroxyMeDIP assay vs ELISA).
Overall, it is clear that the methylation of DNA is critical to
epigenetic processes associated not only with normal brain
function and aging but also with AD. Although we still lack
information regarding the speciﬁc patterns of methylation in
speciﬁc neuronal populations of key brain nuclei, transcriptomic
alterations in AD via epigenetic deregulations could drive the
induction of alterations in molecular cascades that will eventually
end up with the induction or acceleration of the appearance of AD
hallmarks and, consequently dementia and neurodegeneration.
The ongoing search for more epigenetic modiﬁcations95 will
require the development of new technologies to improve our
knowledge of the speciﬁc role of DNA modiﬁcation in brain
function. Data from a combination of better analyses of human AD
samples that take into account the heterogeneity of brain tissue
by studying the neuroepigenome via strategies such as single-cell
epigenomics,96 and base-resolution whole-genome studies of
large cohorts of human samples,97,98 are sure to be of value for
designing early therapeutic interventions aimed at preventing the
initial alterations of and, ultimately, AD itself.
PARKINSON’S DISEASE
PD is a relatively frequent form of neurodegeneration with a
prevalence of ~ 2% worldwide in the over 70 years of age,99
affecting more than four million people100 and with an estimated
incidence of 1% in people over 60 years of age.101 PD is
characterized by a plethora of symptoms progressing from non-
motor changes (olfactory impairments, sleep alterations, constipa-
tion and depression)102 to motor alterations (tremor, bradykinesia,
rigidity).103 Although the diagnosis of PD is based on the
appearance of the motor symptoms, current knowledge indicates
that the psychiatric manifestations of the disorder are the ﬁrst to
appear. At the pathophysiological level, PD is characterized by an
accumulation of α-synuclein in diverse brain areas, accompanied
by a loss of dopaminergic neurons in the substantia nigra and
catecholaminergic neurons in the locus coeruleus.15,102 The brains
of PD patients often present Lewy bodies, which are formed by
the accumulation of α-synuclein, and by parkin and ubiquitin
aggregates.104 Although its cause remains unknown, it has been
hypothesized that the disorder is inﬂuenced by the interaction of
genetic and non-genetic factors, both contributing to a progres-
sive neuronal loss in different brain areas. Monogenic cases of PD,
directly affecting ~ 5–10% of all cases, have been described for
mutations in the ATP13A2, DJ1, LRRK2, PARK2, PINK1 and UCHL-1
genes.105,106 In addition to the autonomic dominant mutations,
several risk loci have also been identiﬁed.107 However, the
majority of PD cases are sporadic, their origin being unknown.
Figure 3. Representation of the known intracellular location of
proteins encoded by genes undergoing aberrant DNA methylation
in dementia. Nuclear, cytosolic or membrane-associated genes both
in neurons (blue) or glia (principally astrocytes and microglia; in pale
brown) are illustrated, together with secreted (extracellular) proteins
(green).
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Parkinson’s disease dementia (PDD) is a late symptom affecting
up to 80% of patients with PD.108 Clinical manifestations of PDD
not only include the classic memory impairments but also a
myriad of phenotypes, such as alterations of the executive
function, deﬁcits in recognition memory, attention processes
and visual perception, often accompanied by visual hallucinations
and cognitive ﬂuctuations.109 However, the mechanisms under-
lying PDD are still not understood. Recently published data on the
epigenetics of PD have suggested the involvement of this
regulatory mechanism in the etiopathology of the disorder,
although the exact involvement of DNA methylation in the
initiation or progression of PD is still unclear.
Most of the analyses of the role of DNA methylation in PD/PDD
have conﬁned themselves to investigating the regulation of genes
causing PD. The promoter of SNCA, the gene responsible for the
expression of the presynaptic α-synuclein, is hypomethylated at
intron 1 in several brain areas such as the substantia nigra and
cortex of PD patients.110–112 This epigenetic regulation of SNCA
could explain the higher level of expression of α-synuclein found
in PD brains and other neurodegenerative disorders that feature
dementia.113 Interestingly, α-synuclein is capable of sequestering
DNMT1 from the nucleus, a factor that could explain the global
hypomethylation observed in human PD brains.112 Nonetheless,
more in-depth studies of SNCA epigenomic regulation are
required, as other methylomic studies of PD have not been able
to detect differences in SNCA intron 1 methylation levels.41,114
Besides SNCA, no other genes directly related to PD have been
identiﬁed as being regulated via methylation of their promoters.
Several studies using genome-wide approaches have failed to
identify differences in DNA methylation of LRKK2, Parkin, UCHL-1,
MAPT and ATP12A2 promoters.41,115,116 However, genes such as
PARK16/lq32, GPNMB and STX1B, associated with an increased risk
of PD, showed altered methylation levels in PD brains.115 Other
analyses taking genome-wide approaches identiﬁed alterations of
several genes at the methylation level.41,117 Interestingly, methyla-
tion levels of the NPAS2 gene, a clock gene, were lower in PD
brains.118 Sleep disturbances are a core symptom of PD119 and
NPAS2 is involved in sleep regulation.120,121
Little is known about 5 hmC changes in the brain of PD patients;
the only data available have come from the 6-hydroxydopamine-
induced rat model of PD. Using that model, Zhang et al.122 were
unable to ﬁnd any difference in the levels of 5 hmC in rat
brains.122 Therefore, the potential involvement of 5 hmC in the
causes or consequences of PD remains to be determined. Overall,
little is known about aberrant DNA (hydroxy)methylation patterns
in PD/PDD but the information obtained highlights the need for
further research on the neuroepigenomics of PD, as the data
collected so far indicate that epigenetic processes may mediate
some of the molecular alterations observed in this pathology.
DEMENTIA WITH LEWY BODIES
Besides PD, there are other forms of dementia induced by the
formation of Lewy bodies (abnormal aggregates of proteins,
principally α-synuclein). DLB is a common form of dementia that
differs from PD by the absence of parkinsonism and the
progression of the pathology. PD and DLB are classiﬁed together
as Lewy body dementias and are considered as a continuum
rather than as distinct diseases, DLB being an early manifestation
of dementia in PD patients.108 DLB is the second most common
form of age-related dementia, accounting for an estimated 16–
24% of all dementias.123 Although there is still no clear
information about its neuropathological changes, DLB shares
several pathological marks with AD, PD and PDD: the presence of
altered Aβ levels both in DLB and AD has been described, and
several mutations associated with AD or PD have also been related
to DLB, including mutations in APP, PSEN1/2, SNCA and LRRK2.40,124
The clinical diagnosis of DLB focuses on the cognitive impairments
associated with confusion and attentional deﬁcits, especially those
related to visuospatial function.125 These symptoms are often
accompanied by psychiatric alterations such as hallucinations,
apathy and anxiety.126,127
Although the molecular driving events responsible for the
development of DLB are still unknown, several authors have
identiﬁed gene networks that are epigenetically deregulated in
DLB. Humphries et al.75 demonstrated that DLB brain tissue
features DNA methylation alterations in genes related to synaptic
function and behavioral response. This is not surprising since
cognitive decline is one of the major alterations occurring in
DLB.9,128 Although Aβ overproduction is common in DLB, one
study failed to describe DNA methylation changes in human
brains of DLB patients in the APP gene53 or other AD-related
genes.54 Sleep disturbances are also common in DLB, especially
rapid eye movement sleep behavior disorder.129 It is of note that
DNA methylation deregulation of the clock genes PER1 and CRY1,
which help regulate the circadian cycle and sleep,130 have been
reported in DLB blood samples,131 although it will be necessary to
analyze the effects on the central circadian clock. Desplats et al.112
described a global hypomethylation state in DLB post-mortem
brain samples that probably arises from the reduction in Dnmt1
nuclear levels. The same authors not only described the general
hypomethylation state but also reported that the promoter of the
SNCA and SEPW1 genes, which are associated with PD,110,111,132
was also hypomethylated in DLB. Very recently, our team reported
that the DNA methylation level of the promoter of ANK165 was
altered in DLB, along with genes related to several pathways, such
as MAPK, ErbB, neurotrophin, mTOR, p53 signaling and regulation
of the actin cytoskeleton.41
In conclusion, further analysis of the epigenetic alterations in
DLB is required. Owing to the molecular alterations common to
that disorder, PDD and AD, the identiﬁcation of epigenetically
deregulated genes common to all these disorders41 will provide
invaluable knowledge of the early changes in DLB. A better
understanding of aberrant DNA methylation, and an analysis of
5 hmC speciﬁc to DLB are necessary to enable the better
stratiﬁcation and diagnosis108 of patients, and to accelerate the
development of deﬁnitive therapeutic approaches.
FRONTOTEMPORAL DEMENTIA
FTD is the second most common form of neurodegenerative
disease and the third most common form of dementia, after AD
and Lewy body dementias (PDD and DLB). It has an estimated
prevalence of 3– 26% worldwide in people older than 65 years of
age.133 FTD is a heterogeneous disorder comprising various
subtypes, including behavioral-variant frontotemporal dementia
(the most common form of the disease, which accounts for ~ 70%
of the cases of FTD) and the primary progressive aphasias,
including the semantic-variant primary progressive aphasias and
the non-ﬂuent variant primary progressive aphasias.134,135 Clinical
features of FTD vary depending on the subtype of the disorder,
although symptoms may converge. In general, FTD is character-
ized by the presence of cognitive and executive impairments,
spatial skills and memory deﬁcits, decline in social conduct and
deﬁcits of speech.136 Around 10% of FTD patients develop motor
neuron disease and early parkinsonisms.133 All these symptoms
are associated with a bilateral frontal and anterior temporal lobe
degeneration (frontotemporal lobar degeneration; FTLD), and
degeneration of the striatum. At the histological level, FTD is
characterized by neuronal loss (especially of large cortical nerve
cells) and gliosis accompanied by microvacuolar changes. Other
frequently observed alterations are the presence of argyrophilic
neuronal inclusions, known as Pick bodies, which are positive for
Tau and ubiquitin proteins, and swollen cells.133,136,137
Approximately 40% of FTD patients report a history of dementia
in the family.138 The most frequent mutations are found in the
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microtubule-associated protein Tau139 (MAPT) and in the growth
factor progranulin (GRN) gene140,141 (which accounts for450% of
the inherited cases) and on the gene of the chromosome 9 open
reading frame 72 (ref. 142) (C9orf72; ~ 25% of the cases). Other
rare mutations appear in genes such as TARDBP, FUS, CHMP2B,
TREM2 and VCP.133,143 However, most FTD cases are sporadic, with
molecular alterations of unknown origin.
Although a genome-wide analysis of the methylomic alterations
in FTD has not been undertaken, some groups have investigated
the role of DNA methylation in the regulation of speciﬁc genes
associated with the risk of FTD. Two of the most prevalent
mutated genes, GRN and C9orf72, have been found in aberrant
methylomic state in FTD. The GRN gene is hypermethylated in FTD
brains relative to age-matched controls, but notably, also in
comparison with AD and PD samples.144 The increased
methylation was correlated with lower levels of GRN protein in
the frontal cortex of FTD patients. Another of the genes associated
with FTD, C9orf72, is epigenetically altered in patients’ brains.
Expansion of the G4C2 repeat located in the proximal region of
C9orf72 is a pathological common cause of FTD.145 Aberrant
hypermethylation has been described in the G4C2 repeat,
146 and
in the CpG island ﬂanking the region of C9orf72.147–150 The size of
the G4C2 repeat is positively correlated with the level of
hypermethylation.151 This hypermethylation correlates positively
with a reduced neuronal loss, thus pointing out that the
downregulation of the genes could have a protective effect in
the hippocampus and frontal cortex of FTD patients’ brains.152,153
Banzhaf-Strathmann et al.144 also described the overexpression of
DNMT3a in FTD brain samples, which might explain the
hypermethylation state of both GRN and C9orf72 genes. Other
Table 1. DNA (hydroxy)methylation alterations in dementia (human brain studies only)
Gene Regulation Disorder Brain region Methods References
ABCA7 Increased 5mC AD Prefrontal cortex BS array 57
ANK1 Increased 5mC AD Entorhinal and prefrontal cortex WGBS, BS array, pyrosequencing 41,49,65
Reduced 5mC DLB Prefrontal cortex WGBS, BS array, pyrosequencing 41
Increased 5hmC AD Prefrontal cortex WG 5 hmC-enriched seq 89
APP Reduced 5mC AD Parietal cortex, temporal lobe and cerebellum MSRE-SB, pyrosequencing 51–53
BDNF Increased 5mC AD Prefrontal cortex MSRE-PCR 66
BIN1 Increased 5mC AD Entorhinal and prefrontal cortex BS array 49,57
Increased 5hmC AD Prefrontal cortex WG 5 hmC-enriched seq 89
C9orf72 Increased 5mC FTD Frontal cortex, temporal cortex, motor cortex,
cerebellum
MSRE-PCR, BS-seq, MSRE-SB 149,150,152
COX2 Reduced 5mC AD Prefrontal cortex MSRE-PCR 49,66
CREB Increased 5mC AD Prefrontal cortex MSRE-PCR 66
DIP2A Increased 5mC AD Entorhinal and prefrontal cortex BS array 49
Reduced 5hmC AD Prefrontal cortex WG 5 hmC-enriched seq 89
DNMT1 Increased 5mC AD Prefrontal cortex BS-MALDI 56
DUSP22 Increased 5mC AD Hippocampus BS array, pyrosequencing 59
Reduced 5hmC AD Prefrontal cortex WG 5 hmC-enriched seq 89
DUSP6 Increased 5mC AD Superior temporal gyrus BS array 60
GPNMB Reduced 5mC PD Fronta cortex, cerebellum BS array 115
GRN Increased 5mC FTD Frontal cortex BS-MALDI 144
HLA-DRB5 Increased 5mC AD Prefrontal cortex BS array 57
IGFBP7 Reduced 5mC AD Prefrontal cortex MeDIP 79
MT-ND1 Reduced 5mC AD Entorhinal cortex and substantia nigra MeDIP 94
MTHFR Increased 5mC AD Prefrontal cortex BS-MALDI 56
NF-kB Reduced 5mC AD Entorhinal and prefrontal cortex BS array, MSRE-PCR 49,66
PARK16/lq32 Reduced 5mC PD Fronta cortex, cerebellum BS array 115
PSEN1 Reduced 5mC AD Prefrontal cortex BS-MALDI 56
RHBDF2 Increased 5mC AD Entorhinal and prefrontal cortex WGBS, BS array, pyrosequencing 41,49
SEPW1 Reduced 5mC DLB Frontal cortex ELISA, MS-PCR 112
SERPINF1 Increased 5mC AD Entorhinal and prefrontal cortex BS array 49
SERPINF2 Increased 5mC AD Entorhinal and prefrontal cortex BS array 49
SLC24A4 Increased 5mC AD Prefrontal cortex BS array 57
SNCA Reduced 5mC PD Substantia nigra and cortex BS-seq, ELISA, MS-PCR 110–112
Reduced 5mC DLB Frontal cortex ELISA, MS-PCR 112
SORBS3 Increased 5mC AD Entorhinal and prefrontal cortex BS array, pyrosequencing,
MS-PCR
62,64
SORL1 Increased 5mC AD Prefrontal cortex BS array 57
SPTBN4 Increased 5mC AD Frontal cortex BS array, pyrosequencing 62
STX1B Increased 5mC PD Fronta cortex, cerebellum BS array 115
TBXA2R Increased 5mC AD Frontal cortex BS array, pyrosequencing,
MS-PCR
62,64
TMEM59 Reduced 5mC AD Frontal cortex BS array 58
TREM2 Increased 5mC AD Hippocampus BS-seq 71
Increased 5hmC AD Hippocampus 5hMeDIP 71
Abbreviations: AD, Alzheimer’s disease; BS array, bisulﬁte-modiﬁed DNA based arrays; BS-MALDI, bisulﬁte matrix-assisted laser desorption/ionization; BS-seq,
bisulﬁte sequencing; DLB, dementia with Lewy bodies; ELISA, enzyme-linked immunosorbent assay; FTD, frontotemporal dementia; 5mC, 5-methylcystosine;
5hmC 5-hydroxymethylcytosine; 5hMeDIP; 5-hydroxymethylated DNA immunoprecipitation; MeDIP, methylated DNA immunoprecipitation; MS-PCR,
methylation speciﬁc PCR; MSRE-PCR, methylation-sensitive restriction enzyme PCR; MSRE-SB, methylation-sensitive restriction enzyme southern blot; PD,
Parkinson’s disease; WG 5 hmC-enriched seq, whole-genome sequencing analysis of 5-hydroxymethylcytosine-enriched sequences; WGBS, whole-genome
bisulﬁte sequencing.
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genes associated with FTD, such as APP, PSEN1 and MAPT, did not
show any methylation differences in FTD brain samples compared
with age-matched controls.54
The lack of any speciﬁc disease-modifying treatment for FTD
makes it clear that more in-depth epigenetic analysis is necessary
if we are to understand the role of DNA methylation as a potential
driving event in this brain disorder. Genome-wide analysis of 5 mC
and 5 hmC in different areas of post-mortem brain tissue will yield
invaluable insights into potential new gene candidates that are
epigenetically deregulated and simultaneously improve patient
stratiﬁcation, helping to differentiate FTD more accurately from
other dementias.
CONCLUSIONS AND FUTURE PERSPECTIVES
Dementia covers a wide spectrum of cognitive abnormalities
that arise as a clinical consequence of disorders such as AD,
PD, DLB and FTLD. However, our knowledge of its etiology is
rather limited and no effective treatments to prevent or revert
this condition have been described so far. Dementias are age-
associated disorders that, due to the progressive aging of our
societies, are likely to increase in incidence.3 Disorders such
as AD, PD, DLB and FTLD not only share dementia as one of their
core clinical manifestations but also have some molecular
alterations in common, implying the existence of similar driving
events that may diverge later, during the progression of each
disorder. For example Aβ accumulations are considered a hallmark
of AD but are also present in DLB; Tau hyperphosphorylation is
observed not only in AD but also in PD and DLB; and α-synuclein
inclusions are found in PD, DLB and AD.154–158
The importance of epigenetic mechanisms in learning and
memory processes9,128,159 has prompted the scientiﬁc community
to analyze the role of the epigenome in neurological diseases.15
Accordingly, it has been proposed (the LEARn hypothesis) that
epigenetic alterations during the lifespan would disturb gene
expression over the long term, in an accumulative way, acting as a
‘seed’ for the development of disorders such as dementia and
neurodegeneration.7 Thus, information about the epigenetic
dysregulations of brain function would provide invaluable knowl-
edge about the origin and progression of brain disorders,
contributing to the development of effective therapeutic inter-
ventions. In this context, our laboratory has recently identiﬁed a
network of genes undergoing an aberrant methylomic state of
their promoters that is common to AD, PD and DLB.41 While this is
the ﬁrst genome-wide demonstration of epigenetic alterations
being shared by these disorders, several other alterations
common to some of them have been described before (Tables 1
and 2). For example, ANK1, a gene associated with microglia
activation, is epigenetically altered in AD41,49,65 and DLB.41 Other
examples include the gene SNCA, which is aberrantly methylated
in PD and DLB,112 and TREM2, a gene mutated in FTD, which is
epigenetically altered in AD.71 In addition, α-synuclein can
associate with DNMT1, sequestering it in the cytoplasm, resulting
in global DNA hypomethylation. This effect of α-synuclein was
found not only in PD cases but also in DLB.112 As α-synuclein can
also accumulate in AD,154 this mechanism might also contribute to
the global DNA hypomethylation seen in the latter. However,
more in-depth analysis and genome-wide approaches are
essential for understanding the role of aberrant epigenomes in
dementia, especially in little understood disorders such as FTD and
DLB. This is critical if we are to identify a causative role for DNA
Table 2. GO analysis using the topGo tool for the genes with described epigenetic alterations in dementia
Ontology GO terms P-value Genes
Biological process Regulation of cellular component
organization
4.4e− 09 ABCA7, ANK1, BIN1, DNMT1, GRN, IGFBP7, MTHFR, PSEN1, SERPINF1,
SERPINF2, SNCA, SORBS3, SORL1, SPTBN4, STX1B, TMEM59, TREM2
Vesicle-mediated transport 9.1e− 08 ABCA7, ANK1, APP, BIN1, C9orf72, GRN, PSEN1, SERPINF2, SNCA, SORL1,
SPTBN4, STX1B, TREM2
Regulation of protein modiﬁcation
process
2.4e− 07 ABCA7, APP, DNMT1, DUSP22, DUSP6, MTHFR, PSEN1, SERPINF2, SNCA,
SORBS3, SORL1, SPTBN4, TMEM59, TREM2
β-Amyloid formation 7.0e− 07 ABCA7, PSEN1, SORL1
Negative regulation of protein
metabolic process
8.2e− 07 ABCA7, APP, DNMT1, DUSP22, DUSP6, PSEN1, SERPINF1, SERPINF2, SNCA,
SORL1, TMEM59
Negative regulation of proteolysis 1.6e− 06 APP, PSEN1, SERPINF1, SERPINF2, SNCA, SORL1, TMEM59
Regulation of cellular protein metabolic
process
1.7e− 06 ABCA7, APP, DNMT1, DUSP22, DUSP6, MTHFR, PSEN1, SERPINF1, SERPINF2,
SNCA, SORBS3, SORL1, SPTBN4, TMEM59, TREM2
Regulation of MAPK cascade 3.5e− 06 ABCA7, DUSP22, DUSP6, PSEN1, SERPINF2, SORBS3, SORL1, SPTBN4, TREM2
Positive regulation of protein metabolic
process
3.6e− 06 ABCA7, APP, DNMT1, DUSP22, DUSP6, PSEN1, SERPINF2, SNCA, SORBS3,
SORL1, SPTBN4, TREM2
Regulation of protein metabolic
process
4.1e− 06 ABCA7, APP, DNMT1, DUSP22, DUSP6, MTHFR, PSEN1, SERPINF1, SERPINF2,
SNCA, SORBS3, SORL1, SPTBN4, TMEM59, TREM2
Molecular function Endopeptidase inhibitor activity 1.7e− 04 APP, SERPINF1, SERPINF2, SNCA
Tau protein binding 1.8e− 04 BIN1, SNCA
Endopeptidase regulator activity 1.9e− 04 APP, SERPINF1, SERPINF2, SNCA
Peptidase inhibitor activity 2.0e− 04 APP, SERPINF1, SERPINF2, SNCA
Enzyme binding 2.7e− 04 ANK1, APP, BIN1, C9orf72, DNMT1, SERPINF2, SNCA, SORL1, SPTBN4, STX1B
Peptidase regulator activity 4.1e− 04 APP, SERPINF1, SERPINF2, SNCA
Serine-type endopeptidase inhibitor
activity
5.2e− 04 APP, SERPINF1, SERPINF2
Structural constituent of cytoskeleton 6.3e− 04 ANK1, SORBS3, SPTBN4
Spectrin binding 7.9e− 04 ANK1, SPTBN4
Tyrosine/serine/threonine phosphatase
activity
2.7e− 03 DUSP22, DUSP6
Abbreviations: GO, gene ontology; MAPK, mitogen-activated protein kinase. The top 10 more signiﬁcant terms at the biological process and molecular
function characterization levels are shown. P-values show the statistical signiﬁcance of the enrichment of gene ontology terms with analyzed genes.
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methylation in the appearance of neurodegenerative diseases by
proving that environmental factors (life experiences, toxins, other
disorders) may alter our epigenome in an accumulative way that
may eventually end by developing dementia (the LEARn
hypothesis7).
Epigenetic brain changes are strong correlated with normal
aging,11,160,161 suggesting that DNA methylation patterns are
modiﬁed to start senescence programs.162 Interestingly, accelerate
epigenetic aging has been described in dementia-related
disorders such as AD163 and PD.164 Together with the fact that
age is the most important risk factor for many dementia-related
disorders, these data suggest a strong association between
dementia and an accelerated epigenetic aging.
The young ﬁeld of neuroepigenomics13 is increasingly identify-
ing new druggable pathways and targets in dementia, demon-
strating the importance of the epigenetic component in the
healthy brain and in brain disorders.165 The epigenetic discoveries
made in the ﬁeld of dementia in recent years suggest that
neuroepigenomic alterations are fundamental in dementia.
Several disorders that feature dementia share common aberrant
DNA methylation pattern,41 suggesting that these genes could be
responsible for the common clinical symptoms presented.
However, several methodological and biological drawbacks need
to be addressed to properly understand the alterations of the
epigenome that occur in dementia. This, together with more in-
depth proper cross-disorder studies, will eventually open up the
potential for designing effective therapeutic interventions to
prevent or revert such pathologies. Until now, all human
neuroepigenetic studies have been carried out using post-
mortem brain tissue samples. Customarily, grey matter (or often
a mixture of white and grey matter) is used for DNA extraction and
DNA methylation changes are subsequently analyzed using
bisulﬁte conversion or other techniques.166 Furthermore, the
heterogeneity of brain cells167,168 makes more speciﬁc types of
preparation essential if we are to understand the speciﬁc aberrant
methylomes associated with dementia in particular cell popula-
tions. This limitations are probably the base of current discre-
pancies found in the literature on the epigenomics of dementia
(different brain sections, even from the same brain area, thus
different cellular composition; different ‘life stages’ of the patients,
etc). Other possible confounders, such geographic distribution of
patients,169 sex170 and so on, may be important to explain
discrepancies. On the other hand, future studies need to address
properly the correlation between neuropathological stage of the
disease studied and the changes in (hydroxyl)methylation to
properly understand the pathological evolution of the disorder
under the epigenomic point of view. Other critical issue is that
classically, DNA methylation patterns have been interrogated
through sodium bisulﬁte-treated DNA. This chemical agent
transforms ‘unprotected’ cytosines to uracils. However, both
methylation and hydroxymethylation modiﬁcations protect such
cytosines to be transformed. Thus, bisulﬁte-based analysis do not
allow to differentiate between 5 mC and 5 hmC, although the data
generated on 5 hmC indicates the importance of this modiﬁcation
by itself,161 especially in the brain.171 Recently, a commercially
available kit (TrueMethyl Array Kit (Cambridge Epigenetix, Cam-
bridge, UK)) has been developed allowing for the differentiation
between 5 mC and 5 hmC.172 Together with the development of
new technologies for interrogating the epigenome (i.e. nanopore
sequencing173), this kit will eventually increase the current
knowledge of the role of 5-hydroxymethylation on dementia,
and will force to revise previous published data on DNA
methylation on brain disorders, possibly helping to understand
current discrepancies. The epigenomic analysis of brain seek to
establish strong associations between the (hydroxyl)methylome
and the human disorder, but those ﬁndings need to be validated
to conﬁrm if a speciﬁc alteration has a causative role on the
disease. Together with the lack of longitudinal studies in human
samples that would allow to establish the disorder-causality role of
the epigenetic alterations observed, it is clear that the need of
better ‘humanized’ dynamic models of the pathologies could
improve our understanding of dementia. Research with induced
pluripotent stem cells differentiated to speciﬁc neuronal
populations174 or single-cell epigenomics175 will undoubtedly
reveal a completely new level of complexity and a set of genes
that are altered in dementia-associated pathologies by identifying
causal associations between neuronal dysfunctions, gene expres-
sion and epigenetic (de)regulation. Recent advances in genetic
and epigenetic editing through technologies such CRISPR/
Cas9176,177 will undoubtfully provide a powerful experimental tool
that will allow to validate epigenetically altered targets to improve
the possible causality of DNA methylome alteration in dementia.
The brain is an extraordinary organ showing high levels of
epigenetic features, such as non-CpG methylation.21,178 The
understanding of the role of these non-CpG changes along with
the more detailed dissection of the speciﬁc role of 5-methylcy-
tosine, 5-hydroxymethylcytosine and newly discovered marks,
such as the N6-methyladenine,95,179 will help the scientiﬁc
community understand the epigenetic mechanisms underpinning
dementia. The recent analysis of human reference epigenomes180
will enable future neuroepigenomics research to exploit the full
potential of alterations in DNA methylation patterns in speciﬁc
genes and cell populations to enable better patient diagnosis, and
the stratiﬁcation and treatment of dementia and other brain
disorders.
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